UK agency may recommend Sutent for some stromal tumours
This article was originally published in Scrip
Executive Summary
The National Institute for health and Clinical Excellence is preparing to recommend Pfizer's Sutent (sunitinib malate) as a treatment option for people with unresectable and/or metastatic malignant gastrointestinal stromal tumours if treatment with imatinib (Novartis's Glivec) has failed because of resistance or intolerance and if they have an Eastern Cooperative Oncology Group performance status of 0 or 1.